{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:49:36Z","timestamp":1792090176994,"version":"4.4.0"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003093","name":"Ministry of Higher Education, Malaysia","doi-asserted-by":"publisher","award":["FRGS\/1\/2018\/STG05\/MUSM\/02\/3."],"award-info":[{"award-number":["FRGS\/1\/2018\/STG05\/MUSM\/02\/3."]}],"id":[{"id":"10.13039\/501100003093","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003093","name":"Ministry of Higher Education, Malaysia","doi-asserted-by":"publisher","award":["FRGS\/1\/2018\/STG05\/MUSM\/02\/3."],"award-info":[{"award-number":["FRGS\/1\/2018\/STG05\/MUSM\/02\/3."]}],"id":[{"id":"10.13039\/501100003093","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003093","name":"Ministry of Higher Education, Malaysia","doi-asserted-by":"publisher","award":["FRGS\/1\/2018\/STG05\/MUSM\/02\/3."],"award-info":[{"award-number":["FRGS\/1\/2018\/STG05\/MUSM\/02\/3."]}],"id":[{"id":"10.13039\/501100003093","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003093","name":"Ministry of Higher Education, Malaysia","doi-asserted-by":"publisher","award":["FRGS\/1\/2018\/STG05\/MUSM\/02\/3."],"award-info":[{"award-number":["FRGS\/1\/2018\/STG05\/MUSM\/02\/3."]}],"id":[{"id":"10.13039\/501100003093","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Gene Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The astounding success of mRNA empowers the diverse application of mRNA therapeutics in multiple genetic disorders. Besides the vaccines, the rational design of mRNA drugs has been explored widely to target the undruggable gene therapy for managing cancer. Restoration of the p53 tumor suppressor gene via introducing foreign p53-mRNA therapeutics may inhibit the growth and development of tumors. Since the development of mRNA transporting vehicles, liposome-based nanoparticles are the mainstay and are widely used in several ex vivo and clinical studies. But the delivery of mRNA outside the immune cells and hepatocytes for protein replacement therapy through systemic administartion is very limited and requires additional optimization. Here, we modified classical LNP (lipid nanoparticles) with SSNs (strontium sulfite nanoparticles) and complexed the LNP with p53 mRNA to improve the delivery efficiency of p53 mRNA. We assumed that restoration of p53 function in breast tumor cells might improve antitumor efficacy against breast cancer. We screened the SSNs-LNP to get the favorable physicochemical properties and to improve the delivery efficiency. The SSNs-LNP showed a threefold increase of luciferase gene expression in breast cancer cell lines compared to the classical LNP. In the animal model, the SSNs-LNP improved the biological stability and tumor targeting efficiency and restored the expression of p53, resulting in a significant reduction of tumor volume. Thus, we anticipate that the hybrid SSNs-LNP particles could be a translatable nanocarrier system in transporting mRNA drugs for the treatment of cancers.<\/jats:p>","DOI":"10.1038\/s41417-026-01085-w","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T11:02:07Z","timestamp":1792062127000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Restoration of p53 function via hybrid strontium sulfite nanoparticles modified LNP improves the antitumor efficacy in breast cancers"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0322-2058","authenticated-orcid":false,"given":"Md Emranul","family":"Karim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark M. Banaszak","family":"Holl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Corrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5705-841X","authenticated-orcid":false,"given":"Ezharul Hoque","family":"Chowdhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,15]]},"reference":[{"key":"1085_CR1","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1038\/ncb1105-1054","volume":"7","author":"AK Das","year":"2005","unstructured":"Das AK, Carmichael GG. Unleash the messenger. Nat Cell Biol. 2005;7:1054\u20135.","journal-title":"Nat Cell Biol"},{"key":"1085_CR2","doi-asserted-by":"crossref","unstructured":"Liu B, Pan T. Building better mRNA for therapeutics. Nat Biotechnol. 2025;43:1058\u201360.","DOI":"10.1038\/s41587-024-02424-8"},{"key":"1085_CR3","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1038\/s41587-022-01491-z","volume":"40","author":"E Rohner","year":"2022","unstructured":"Rohner E, Yang R, Foo KS, Goedel A, Chien KR. Unlocking the promise of mRNA therapeutics. Nat Biotechnol. 2022;40:1586\u2013600.","journal-title":"Nat Biotechnol"},{"key":"1085_CR4","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.ymthe.2019.02.012","volume":"27","author":"PS Kowalski","year":"2019","unstructured":"Kowalski PS, Rudra A, Miao L, Anderson DG. Delivering the messenger: advances in technologies for therapeutic mRNA delivery. Mol Ther. 2019;27:710\u201328.","journal-title":"Mol Ther"},{"key":"1085_CR5","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/nrd4278","volume":"13","author":"U Sahin","year":"2014","unstructured":"Sahin U, Karik\u00f3 K, T\u00fcreci \u00d6. mRNA-based therapeutics-developing a new class of drugs. Nat Rev Drug Discov. 2014;13:759\u201380.","journal-title":"Nat Rev Drug Discov"},{"key":"1085_CR6","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrd.2017.243","volume":"17","author":"N Pardi","year":"2018","unstructured":"Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines\u2014a new era in vaccinology. Nat Rev Drug Discov. 2018;17:261\u201379.","journal-title":"Nat Rev Drug Discov"},{"key":"1085_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/natrevmats.2017.56","volume":"2","author":"KA Hajj","year":"2017","unstructured":"Hajj KA, Whitehead KA. Tools for translation: non-viral materials for therapeutic mRNA delivery. Nat Rev Mater. 2017;2:17056.","journal-title":"Nat Rev Mater"},{"key":"1085_CR8","doi-asserted-by":"crossref","first-page":"8099","DOI":"10.1021\/acs.nanolett.5b03528","volume":"15","author":"B Li","year":"2015","unstructured":"Li B, Luo X, Deng B, Wang J, McComb DW, Shi Y, et al. An orthogonal array optimization of lipid-like nanoparticles for mRNA delivery in vivo. Nano Lett. 2015;15:8099\u2013107.","journal-title":"Nano Lett"},{"key":"1085_CR9","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/nature21428","volume":"543","author":"N Pardi","year":"2017","unstructured":"Pardi N, Hogan MJ, Pelc RS, Muramatsu H, Andersen H, DeMaso CR, et al. Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. Nature. 2017;543:248\u201351.","journal-title":"Nature"},{"key":"1085_CR10","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1021\/acs.nanolett.6b03329","volume":"17","author":"MA Oberli","year":"2017","unstructured":"Oberli MA, Reichmuth AM, Dorkin JR, Mitchell MJ, Fenton OS, Jaklenec A, et al. Lipid nanoparticle assisted mRNA delivery for potent cancer immunotherapy. Nano Lett. 2017;17:1326\u201335.","journal-title":"Nano Lett"},{"key":"1085_CR11","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1002\/anie.201610209","volume":"56","author":"JB Miller","year":"2017","unstructured":"Miller JB, Zhang S, Kos P, Xiong H, Zhou K, Perelman SS, et al. Non-Viral CRISPR\/cas gene editing in vitro and in vivo enabled by synthetic nanoparticle co-delivery of Cas9 mRNA and sgRNA. Angew Chem Int Ed Engl. 2017;56:1059\u201363.","journal-title":"Angew Chem Int Ed Engl"},{"key":"1085_CR12","doi-asserted-by":"crossref","DOI":"10.1016\/j.biotechadv.2020.107534","volume":"40","author":"Y Weng","year":"2020","unstructured":"Weng Y, Li C, Yang T, Hu B, Zhang M, Guo S, et al. The challenge and prospect of mRNA therapeutics landscape. Biotechnol Adv. 2020;40:107534.","journal-title":"Biotechnol Adv"},{"key":"1085_CR13","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/s41568-023-00586-2","volume":"23","author":"C Liu","year":"2023","unstructured":"Liu C, Shi Q, Huang X, Koo S, Kong N, Tao W. mRNA-based cancer therapeutics. Nat Rev Cancer. 2023;23:526\u201343.","journal-title":"Nat Rev Cancer"},{"key":"1085_CR14","doi-asserted-by":"crossref","unstructured":"Li Q, Xing H, Naeem A, Zhang K, Zheng A, Huang Y, et al., editors. Extracellular vesicle-based mRNA therapeutics and vaccines. Exploration. Wiley Online Library; 2025.","DOI":"10.1002\/EXP.20240109"},{"key":"1085_CR15","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s12272-022-01418-x","volume":"45","author":"ME Karim","year":"2022","unstructured":"Karim ME, Haque ST, Al-Busaidi H, Bakhtiar A, Tha KK, Holl MMB, et al. Scope and challenges of nanoparticle-based mRNA delivery in cancer treatment. Arch Pharm Res. 2022;45:865\u201393.","journal-title":"Arch Pharm Res"},{"key":"1085_CR16","doi-asserted-by":"crossref","first-page":"877","DOI":"10.3390\/pharmaceutics13020206","volume":"13","author":"BN Aldosari","year":"2021","unstructured":"Aldosari BN, Alfagih IM, Almurshedi AS. Lipid nanoparticles as delivery systems for RNA-based vaccines. Pharmaceutics. 2021;13:877.","journal-title":"Pharmaceutics"},{"key":"1085_CR17","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1021\/acs.molpharmaceut.8b01290","volume":"16","author":"KH Moss","year":"2019","unstructured":"Moss KH, Popova P, Hadrup SR, Astakhova K, Taskova M. Lipid nanoparticles for delivery of therapeutic RNA oligonucleotides. Mol Pharm. 2019;16:2265\u201377.","journal-title":"Mol Pharm"},{"key":"1085_CR18","doi-asserted-by":"crossref","unstructured":"Jarzebska NT, Mellett M, Frei J, K\u00fcndig TM, Pascolo S. Protamine-based strategies for RNA transfection. Pharmaceutics. 2021;13.","DOI":"10.3390\/pharmaceutics13060877"},{"key":"1085_CR19","doi-asserted-by":"crossref","first-page":"e10374","DOI":"10.1002\/btm2.10374","volume":"8","author":"A Curreri","year":"2023","unstructured":"Curreri A, Sankholkar D, Mitragotri S, Zhao Z. RNA therapeutics in the clinic. Bioeng Transl Med. 2023;8:e10374.","journal-title":"Bioeng Transl Med"},{"key":"1085_CR20","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.ade1444","volume":"9","author":"JR Melamed","year":"2023","unstructured":"Melamed JR, Yerneni SS, Arral ML, LoPresti ST, Chaudhary N, Sehrawat A, et al. Ionizable lipid nanoparticles deliver mRNA to pancreatic \u03b2 cells via macrophage-mediated gene transfer. Sci Adv. 2023;9:eade1444.","journal-title":"Sci Adv"},{"key":"1085_CR21","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s13346-013-0158-7","volume":"4","author":"D Landesman-Milo","year":"2014","unstructured":"Landesman-Milo D, Peer D. Toxicity profiling of several common RNAi-based nanomedicines: a comparative study. Drug Deliv Transl Res. 2014;4:96\u2013103.","journal-title":"Drug Deliv Transl Res"},{"key":"1085_CR22","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.bbrc.2005.03.041","volume":"330","author":"Z Ma","year":"2005","unstructured":"Ma Z, Li J, He F, Wilson A, Pitt B, Li S. Cationic lipids enhance siRNA-mediated interferon response in mice. Biochem Biophys Res Commun. 2005;330:755\u20139.","journal-title":"Biochem Biophys Res Commun"},{"key":"1085_CR23","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jconrel.2006.04.014","volume":"114","author":"H Lv","year":"2006","unstructured":"Lv H, Zhang S, Wang B, Cui S, Yan J. Toxicity of cationic lipids and cationic polymers in gene delivery. J Control Release. 2006;114:100\u20139.","journal-title":"J Control Release"},{"key":"1085_CR24","doi-asserted-by":"crossref","first-page":"e3002105","DOI":"10.1371\/journal.pbio.3002105","volume":"21","author":"AG Hamilton","year":"2023","unstructured":"Hamilton AG, Swingle KL, Mitchell MJ. Biotechnology: overcoming biological barriers to nucleic acid delivery using lipid nanoparticles. PLOS Biol. 2023;21:e3002105.","journal-title":"PLOS Biol"},{"key":"1085_CR25","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.1016\/j.biomaterials.2009.02.050","volume":"30","author":"FT Zohra","year":"2009","unstructured":"Zohra FT, Chowdhury EH, Akaike T. High performance mRNA transfection through carbonate apatite-cationic liposome conjugates. Biomaterials. 2009;30:4006\u201313.","journal-title":"Biomaterials"},{"key":"1085_CR26","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.biomaterials.2015.12.031","volume":"82","author":"S Uchida","year":"2016","unstructured":"Uchida S, Kinoh H, Ishii T, Matsui A, Tockary TA, Takeda KM, et al. Systemic delivery of messenger RNA for the treatment of pancreatic cancer using polyplex nanomicelles with a cholesterol moiety. Biomaterials. 2016;82:221\u20138.","journal-title":"Biomaterials"},{"key":"1085_CR27","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.nano.2010.12.010","volume":"7","author":"F Perche","year":"2011","unstructured":"Perche F, Benvegnu T, Berchel M, Lebegue L, Pichon C, Jaffr\u00e8s PA, et al. Enhancement of dendritic cells transfection in vivo and of vaccination against B16F10 melanoma with mannosylated histidylated lipopolyplexes loaded with tumor antigen messenger RNA. Nanomedicine. 2011;7:445\u201353.","journal-title":"Nanomedicine"},{"key":"1085_CR28","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1001\/jama.2018.19323","volume":"321","author":"AG Waks","year":"2019","unstructured":"Waks AG, Winer EP. Breast cancer treatment: a review. JAMA. 2019;321:288\u2013300.","journal-title":"JAMA"},{"key":"1085_CR29","doi-asserted-by":"crossref","unstructured":"Fahad Ullah M. Breast Cancer: current perspectives on the disease status. In: Ahmad A, editor. Breast cancer metastasis and drug resistance: challenges and progress. Cham: Springer International Publishing; 2019. p. 51\u201364.","DOI":"10.1007\/978-3-030-20301-6_4"},{"key":"1085_CR30","doi-asserted-by":"crossref","unstructured":"Arneth B. Tumor microenvironment. Medicina [Internet]. 2020;56.","DOI":"10.3390\/medicina56010015"},{"key":"1085_CR31","doi-asserted-by":"crossref","first-page":"R921","DOI":"10.1016\/j.cub.2020.06.081","volume":"30","author":"NM Anderson","year":"2020","unstructured":"Anderson NM, Simon MC. The tumor microenvironment. Curr Biol. 2020;30:R921\u2013R5.","journal-title":"Curr Biol"},{"key":"1085_CR32","doi-asserted-by":"crossref","unstructured":"Zhu G, Pan C, Bei J-X, Li B, Liang C, Xu Y, et al. Mutant p53 in cancer progression and targeted therapies. Front Oncol. 2020;10.","DOI":"10.3389\/fonc.2020.595187"},{"key":"1085_CR33","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/358015a0","volume":"358","author":"DP Lane","year":"1992","unstructured":"Lane DP. Cancer. p53, guardian of the genome. Nature. 1992;358:15\u20136.","journal-title":"Nature"},{"key":"1085_CR34","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1126\/science.1905840","volume":"253","author":"M Hollstein","year":"1991","unstructured":"Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science. 1991;253:49\u201353.","journal-title":"Science"},{"key":"1085_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-021-02396-8","volume":"21","author":"HE Marei","year":"2021","unstructured":"Marei HE, Althani A, Afifi N, Hasan A, Caceci T, Pozzoli G, et al. p53 signaling in cancer progression and therapy. Cancer Cell Int. 2021;21:703.","journal-title":"Cancer Cell Int"},{"key":"1085_CR36","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/s41580-019-0110-x","volume":"20","author":"A Hafner","year":"2019","unstructured":"Hafner A, Bulyk ML, Jambhekar A, Lahav G. The multiple mechanisms that regulate p53 activity and cell fate. Nat Rev Mol Cell Biol. 2019;20:199\u2013210.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1085_CR37","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.740578","volume":"11","author":"O Timofeev","year":"2021","unstructured":"Timofeev O. Editorial: mutant p53 in cancer progression and personalized therapeutic treatments. Front Oncol. 2021;11:740578.","journal-title":"Front Oncol"},{"key":"1085_CR38","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41573-022-00571-8","volume":"22","author":"O Hassin","year":"2023","unstructured":"Hassin O, Oren M. Drugging p53 in cancer: one protein, many targets. Nat Rev Drug Discov. 2023;22:127\u201344.","journal-title":"Nat Rev Drug Discov"},{"key":"1085_CR39","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/ncb2641","volume":"15","author":"PAJ Muller","year":"2013","unstructured":"Muller PAJ, Vousden KH. p53 mutations in cancer. Nat Cell Biol. 2013;15:2\u20138.","journal-title":"Nat Cell Biol"},{"key":"1085_CR40","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/humu.20495","volume":"28","author":"A Petitjean","year":"2007","unstructured":"Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P, et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat. 2007;28:622\u20139.","journal-title":"Hum Mutat"},{"key":"1085_CR41","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ccell.2018.11.009","volume":"35","author":"AJ Levine","year":"2019","unstructured":"Levine AJ, Jenkins NA, Copeland NG. The roles of initiating truncal mutations in human cancers: the order of mutations and tumor cell type matters. Cancer Cell. 2019;35:10\u20135.","journal-title":"Cancer Cell"},{"key":"1085_CR42","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/ncb1571","volume":"9","author":"H Song","year":"2007","unstructured":"Song H, Hollstein M, Xu Y. p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM. Nat Cell Biol. 2007;9:573\u201380.","journal-title":"Nat Cell Biol"},{"key":"1085_CR43","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41420-020-0251-x","volume":"6","author":"I Amelio","year":"2020","unstructured":"Amelio I, Melino G. Context is everything: extrinsic signalling and gain-of-function p53 mutants. Cell Death Discov. 2020;6:16.","journal-title":"Cell Death Discov"},{"key":"1085_CR44","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/nature12634","volume":"502","author":"C Kandoth","year":"2013","unstructured":"Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, et al. Mutational landscape and significance across 12 major cancer types. Nature. 2013;502:333\u20139.","journal-title":"Nature"},{"key":"1085_CR45","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3390\/jfb13040211","volume":"13","author":"ME Karim","year":"2022","unstructured":"Karim ME, Chowdhury EH. PEGylated strontium sulfite nanoparticles with spontaneously formed surface-embedded protein corona restrict off-target distribution and accelerate breast tumour-selective delivery of siRNA. J Funct Biomater. 2022;13:211.","journal-title":"J Funct Biomater"},{"key":"1085_CR46","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3390\/pharmaceutics11020089","volume":"11","author":"ME Karim","year":"2019","unstructured":"Karim ME, Shetty J, Islam RA, Kaiser A, Bakhtiar A, Chowdhury EH. Strontium sulfite: a new pH-responsive inorganic nanocarrier to deliver therapeutic siRNAs to cancer cells. Pharmaceutics. 2019;11:89.","journal-title":"Pharmaceutics"},{"key":"1085_CR47","doi-asserted-by":"crossref","first-page":"23259","DOI":"10.1039\/C9NR06835J","volume":"11","author":"A Piloni","year":"2019","unstructured":"Piloni A, Wong CK, Chen F, Lord M, Walther A, Stenzel MH. Surface roughness influences the protein corona formation of glycosylated nanoparticles and alter their cellular uptake. Nanoscale. 2019;11:23259\u201367.","journal-title":"Nanoscale"},{"key":"1085_CR48","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","volume":"20","author":"MJ Mitchell","year":"2021","unstructured":"Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2021;20:101\u201324.","journal-title":"Nat Rev Drug Discov"},{"key":"1085_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-30221-x","volume":"13","author":"R Al-Obaidy","year":"2023","unstructured":"Al-Obaidy R, Haider AJ, Al-Musawi S, Arsad N. Targeted delivery of paclitaxel drug using polymer-coated magnetic nanoparticles for fibrosarcoma therapy: in vitro and in vivo studies. Sci Rep. 2023;13:3180.","journal-title":"Sci Rep"},{"key":"1085_CR50","doi-asserted-by":"crossref","first-page":"840","DOI":"10.2174\/138920021131400105","volume":"14","author":"E Grottkau","year":"2013","unstructured":"Grottkau E, Cai B, Wang X, Yang J, Lin X. Y. Polymeric nanoparticles for a drug delivery system. Curr Drug Metab. 2013;14:840\u20136.","journal-title":"Curr Drug Metab"},{"key":"1085_CR51","doi-asserted-by":"crossref","first-page":"3657","DOI":"10.1016\/j.biomaterials.2010.01.065","volume":"31","author":"C He","year":"2010","unstructured":"He C, Hu Y, Yin L, Tang C, Yin C. Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials. 2010;31:3657\u201366.","journal-title":"Biomaterials"},{"key":"1085_CR52","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1002\/smll.201100442","volume":"7","author":"J Wang","year":"2011","unstructured":"Wang J, Byrne JD, Napier ME, DeSimone JM. More effective nanomedicines through particle design. Small. 2011;7:1919\u201331.","journal-title":"Small"},{"key":"1085_CR53","doi-asserted-by":"crossref","first-page":"8037","DOI":"10.1074\/jbc.M010592200","volume":"276","author":"S Choosakoonkriang","year":"2001","unstructured":"Choosakoonkriang S, Wiethoff CM, Anchordoquy TJ, Koe GS, Smith JG, Middaugh CR. Infrared spectroscopic characterization of the interaction of cationic lipids with plasmid DNA. J Biol Chem. 2001;276:8037\u201343.","journal-title":"J Biol Chem"},{"key":"1085_CR54","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1093\/nar\/gkn1003","volume":"37","author":"R Marty","year":"2009","unstructured":"Marty R, N\u2019Soukpo\u00e9-Kossi CN, Charbonneau D, Weinert CM, Kreplak L, Tajmir-Riahi HA. Structural analysis of DNA complexation with cationic lipids. Nucleic Acids Res. 2009;37:849\u201357.","journal-title":"Nucleic Acids Res"},{"key":"1085_CR55","doi-asserted-by":"crossref","unstructured":"Zheng S, Tu AT. Raman Spectroscopic Identifi cation of Bilirubin-Type Gallstone. Applied Spectroscopy. 1986;40:1099\u2013103.","DOI":"10.1366\/0003702864507639"},{"key":"1085_CR56","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1166\/mat.2014.1161","volume":"3","author":"U Gupta","year":"2014","unstructured":"Gupta U, Singh VK, Kumar V, Khajuria Y. Spectroscopic studies of cholesterol: fourier transform infra-red and vibrational frequency analysis. Mater Focus. 2014;3:211\u20137.","journal-title":"Mater Focus"},{"key":"1085_CR57","doi-asserted-by":"crossref","first-page":"5940","DOI":"10.1039\/C8AN01239C","volume":"143","author":"J Mathurin","year":"2018","unstructured":"Mathurin J, Pancani E, Deniset-Besseau A, Kjoller K, Prater CB, Gref R, et al. How to unravel the chemical structure and component localization of individual drug-loaded polymeric nanoparticles by using tapping AFM-IR. Analyst. 2018;143:5940\u20139.","journal-title":"Analyst"},{"key":"1085_CR58","doi-asserted-by":"crossref","first-page":"5564","DOI":"10.1039\/D2AN01079H","volume":"147","author":"MS Ural","year":"2022","unstructured":"Ural MS, Dartois E, Mathurin J, Desma\u00eble D, Collery P, Dazzi A, et al. Quantification of drug loading in polymeric nanoparticles using AFM-IR technique: a novel method to map and evaluate drug distribution in drug nanocarriers. Analyst. 2022;147:5564\u201378.","journal-title":"Analyst"},{"key":"1085_CR59","doi-asserted-by":"crossref","unstructured":"Bai X, Kang J, Wei S, Wang Y, Liu Y, Yuan B, et al., editors. A pH responsive nanocomposite for combination sonodynamic-immunotherapy with ferroptosis and calcium ion overload via SLC7A11\/ACSL4\/LPCAT3 pathway. Exploration. Wiley Online Library; 2025.","DOI":"10.1002\/EXP.20240002"},{"key":"1085_CR60","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.3390\/ijms18061301","volume":"18","author":"LTM Phuc","year":"2017","unstructured":"Phuc LTM, Taniguchi A. Epidermal growth factor enhances cellular uptake of polystyrene nanoparticles by clathrin-mediated endocytosis. Int J Mol Sci. 2017;18:1301.","journal-title":"Int J Mol Sci"},{"key":"1085_CR61","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1021\/nl403419e","volume":"14","author":"M Mahmoudi","year":"2014","unstructured":"Mahmoudi M, Lohse SE, Murphy CJ, Fathizadeh A, Montazeri A, Suslick KS. Variation of protein corona composition of gold nanoparticles following plasmonic heating. Nano Lett. 2014;14:6\u201312.","journal-title":"Nano Lett"},{"key":"1085_CR62","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1007\/s13346-020-00745-0","volume":"10","author":"G Berrecoso","year":"2020","unstructured":"Berrecoso G, Crecente-Campo J, Alonso MJ. Unveiling the pitfalls of the protein corona of polymeric drug nanocarriers. Drug Deliv Transl Res. 2020;10:730\u201350.","journal-title":"Drug Deliv Transl Res"},{"key":"1085_CR63","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2217\/nnm.15.188","volume":"11","author":"C Corbo","year":"2016","unstructured":"Corbo C, Molinaro R, Parodi A, Toledano Furman NE, Salvatore F, Tasciotti E. The impact of nanoparticle protein corona on cytotoxicity, immunotoxicity and target drug delivery. Nanomedicine (Lond). 2016;11:81\u2013100.","journal-title":"Nanomedicine (Lond)"},{"key":"1085_CR64","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1208\/s12248-020-00464-x","volume":"22","author":"D Chen","year":"2020","unstructured":"Chen D, Ganesh S, Wang W, Amiji M. Protein corona-enabled systemic delivery and targeting of nanoparticles. Aaps J. 2020;22:83.","journal-title":"Aaps J"},{"key":"1085_CR65","doi-asserted-by":"crossref","first-page":"48284","DOI":"10.1021\/acsami.0c12341","volume":"12","author":"SM Pustulka","year":"2020","unstructured":"Pustulka SM, Ling K, Pish SL, Champion JA. Protein nanoparticle charge and hydrophobicity govern protein corona and macrophage uptake. ACS Appl Mater Interfaces. 2020;12:48284\u201395.","journal-title":"ACS Appl Mater Interfaces"},{"key":"1085_CR66","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3390\/toxics7010010","volume":"7","author":"H Al-Busaidi","year":"2019","unstructured":"Al-Busaidi H, Karim ME, Abidin SAZ, Tha KK, Chowdhury EH. Magnesium fluoride forms unique protein corona for efficient delivery of doxorubicin into breast cancer cells. Toxics. 2019;7:10.","journal-title":"Toxics"},{"key":"1085_CR67","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1038\/s41591-022-02061-1","volume":"28","author":"X Huang","year":"2022","unstructured":"Huang X, Kong N, Zhang X, Cao Y, Langer R, Tao W. The landscape of mRNA nanomedicine. Nat Med. 2022;28:2273\u201387.","journal-title":"Nat Med"},{"key":"1085_CR68","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1038\/sj.gt.3302364","volume":"11","author":"N Bessis","year":"2004","unstructured":"Bessis N, GarciaCozar FJ, Boissier MC. Immune responses to gene therapy vectors: influence on vector function and effector mechanisms. Gene Therapy. 2004;11:S10\u2013S7.","journal-title":"Gene Therapy"},{"key":"1085_CR69","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.cell.2020.02.041","volume":"180","author":"KA Fitzgerald","year":"2020","unstructured":"Fitzgerald KA, Kagan JC. Toll-like receptors and the control of immunity. Cell. 2020;180:1044\u201366.","journal-title":"Cell"},{"key":"1085_CR70","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1146\/annurev-immunol-032713-120156","volume":"32","author":"J Wu","year":"2014","unstructured":"Wu J, Chen ZJ. Innate immune sensing and signaling of cytosolic nucleic acids. Ann Rev Immunol. 2014;32:461\u201388.","journal-title":"Ann Rev Immunol"},{"key":"1085_CR71","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3390\/genes10020092","volume":"10","author":"I Freund","year":"2019","unstructured":"Freund I, Eigenbrod T, Helm M, Dalpke AH. RNA modifications modulate activation of innate toll-like receptors. Genes. 2019;10:92.","journal-title":"Genes"},{"key":"1085_CR72","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/sctm.18-0259","volume":"8","author":"ZS Badieyan","year":"2019","unstructured":"Badieyan ZS, Evans T. Concise review: application of chemically modified mRNA in cell fate conversion and tissue engineering. Stem Cell Transl Med. 2019;8:833\u201343.","journal-title":"Stem Cell Transl Med"},{"key":"1085_CR73","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.actbio.2021.06.020","volume":"131","author":"M Gao","year":"2021","unstructured":"Gao M, Zhang Q, Feng XH, Liu J. Synthetic modified messenger RNA for therapeutic applications. Acta Biomater. 2021;131:1\u201315.","journal-title":"Acta Biomater"},{"key":"1085_CR74","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1038\/s41564-019-0653-9","volume":"5","author":"M Lu","year":"2020","unstructured":"Lu M, Zhang Z, Xue M, Zhao BS, Harder O, Li A, et al. N6-methyladenosine modification enables viral RNA to escape recognition by RNA sensor RIG-I. Nat Microbiol. 2020;5:584\u201398.","journal-title":"Nat Microbiol"},{"key":"1085_CR75","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1002\/jcb.25957","volume":"118","author":"Q Li","year":"2017","unstructured":"Li Q, Li X, Tang H, Jiang B, Dou Y, Gorospe M, et al. NSUN2-mediated m5C methylation and METTL3\/METTL14-mediated m6A methylation cooperatively enhance p21 translation. J Cell Biochem. 2017;118:2587\u201398.","journal-title":"J Cell Biochem"},{"key":"1085_CR76","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2:401\u20134.","journal-title":"Cancer Discov"},{"key":"1085_CR77","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/cdd.2017.174","volume":"25","author":"KD Sullivan","year":"2018","unstructured":"Sullivan KD, Galbraith MD, Andrysik Z, Espinosa JM. Mechanisms of transcriptional regulation by p53. Cell Death Differ. 2018;25:133\u201343.","journal-title":"Cell Death Differ"},{"key":"1085_CR78","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.cell.2012.04.026","volume":"149","author":"T Li","year":"2012","unstructured":"Li T, Kon N, Jiang L, Tan M, Ludwig T, Zhao Y, et al. Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence. Cell. 2012;149:1269\u201383.","journal-title":"Cell"},{"key":"1085_CR79","doi-asserted-by":"crossref","first-page":"114","DOI":"10.3390\/biomedicines9020114","volume":"9","author":"S Jahan","year":"2021","unstructured":"Jahan S, Karim ME, Chowdhury EH. Nanoparticles targeting receptors on breast cancer for efficient delivery of chemotherapeutics. Biomedicines. 2021;9:114.","journal-title":"Biomedicines"},{"key":"1085_CR80","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-022-01476-9","volume":"20","author":"GSR Raju","year":"2022","unstructured":"Raju GSR, Pavitra E, Varaprasad GL, Bandaru SS, Nagaraju GP, Farran B, et al. Nanoparticles mediated tumor microenvironment modulation: current advances and applications. J Nanobiotechnol. 2022;20:274.","journal-title":"J Nanobiotechnol"},{"key":"1085_CR81","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3390\/pharmaceutics10020065","volume":"10","author":"ME Karim","year":"2018","unstructured":"Karim ME, Tha KK, Othman I, Borhan Uddin M, Chowdhury EH. Therapeutic potency of nanoformulations of siRNAs and shRNAs in animal models of cancers. Pharmaceutics. 2018;10:65.","journal-title":"Pharmaceutics"},{"key":"1085_CR82","volume":"15","author":"SY Lee","year":"2020","unstructured":"Lee SY, Son JG, Moon JH, Joh S, Lee TG. Comparative study on formation of protein coronas under three different serum origins. Biointerphases. 2020;15:061002.","journal-title":"Biointerphases"},{"key":"1085_CR83","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1248\/bpb.35.111","volume":"35","author":"FT Zohra","year":"2012","unstructured":"Zohra FT, Maitani Y, Akaike T. mRNA delivery through fibronectin associated liposome-apatite particles: a new approach for enhanced mRNA transfection to mammalian cell. Biol Pharm Bull. 2012;35:111\u20135.","journal-title":"Biol Pharm Bull"},{"key":"1085_CR84","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3390\/pharmaceutics11020089","volume":"11","author":"M Karim","year":"2019","unstructured":"Karim M, Shetty J, Islam RA, Kaiser A, Bakhtiar A, Chowdhury EH. Strontium sulfite: a new pH-responsive inorganic nanocarrier to deliver therapeutic siRNAs to cancer cells. Pharmaceutics. 2019;11:89.","journal-title":"Pharmaceutics"}],"container-title":["Cancer Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41417-026-01085-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41417-026-01085-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41417-026-01085-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:01:22Z","timestamp":1792087282000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41417-026-01085-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,15]]},"references-count":84,"alternative-id":["1085"],"URL":"https:\/\/doi.org\/10.1038\/s41417-026-01085-w","relation":{},"ISSN":["0929-1903","1476-5500"],"issn-type":[{"value":"0929-1903","type":"print"},{"value":"1476-5500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,15]]},"assertion":[{"value":"28 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All animal experiments were conducted using protocols approved by the Monash Animal Ethics Committee (Protocol No. MUM AEC\/2023\/27320). All methods were performed in accordance with the relevant institutional guidelines and regulations.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Ethics"}}]}}